Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

被引:191
|
作者
Tong, Xiao [1 ]
Chase, Robert [1 ]
Skelton, Angela [1 ]
Chen, Tong [1 ]
Wright-Minogue, Jackie [1 ]
Malcolm, Bruce A. [1 ]
机构
[1] Schering Plough Res Inst, Dept Virol, Kenilworth, NJ 07033 USA
关键词
hepatitis C virus; protease; inhibitor; resistance; antiviral;
D O I
10.1016/j.antiviral.2005.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
HCV NS3 protease variants resistant to the protease inhibitor SCH 503034 were selected. Three mutations, T54A, V170A and A 156S mutations conferred low to moderate levels of resistance (< 20-fold). Longer exposure (> 10 passages) or selection with higher levels of compound led to the selection of a more resistant variant, A156T (> 100-fold). [Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A., Kwong, A.D., 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279(17), 17508-17514; Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H., Molla, A., 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48(6), 2260-2266.] Combination with IFN-alpha drastically reduced the number of emergent colonies. Resistant colonies showed no change in sensitivity to IFN-alpha. Although the A156T mutation conferred the highest level of resistance to SCH503034, it significantly reduced the colony formation efficiency (CFE) of the mutant replicon RNA, and rendered replicon cells less fit than those bearing wild-type replicons. Replicon cells bearing mutation A156S were less fit than wild-type in co-culture growth competition assays but showed no impact on CFE. The V170A mutation, on the other hand, did not affect replicon fitness in either assay, which was consistent with its emergence as the dominant mutant after 12 months of continuous selection. The reduced fitness of the most resistant variant suggests that it may be rare in naive patients and that development of high-level resistance may be slow. Combination therapy with IFN-alpha should also greatly reduce the potential emergence of resistance. (c) 2006 Elsevier B.V. All rights reserved.
引用
下载
收藏
页码:28 / 38
页数:11
相关论文
共 50 条
  • [41] Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
    Rhee, Soo-Yon
    Boehm, Michael
    Tarasova, Olga
    Di Teodoro, Giulia
    Abecasis, Ana B.
    Sonnerborg, Anders
    Bailey, Alexander J.
    Kireev, Dmitry
    Zazzi, Maurizio
    Shafer, Robert W.
    PATHOGENS, 2022, 11 (05):
  • [42] Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor Regimen
    Fisher, Randall
    van Zyl, Gert U.
    Travers, Simon A. A.
    Pond, Sergei L. Kosakovsky
    Engelbrech, Susan
    Murrell, Ben
    Scheffler, Konrad
    Smith, Davey
    JOURNAL OF VIROLOGY, 2012, 86 (11) : 6231 - 6237
  • [43] TEMPORAL DYNAMIC OF MUTATIONS ASSOCIATED WITH HCV PROTEASE INHIBITORS RESISTANCE IN NATURAL STRAINS OF HIV/HCV COINFECTED INDIVIDUALS
    Messina, E.
    Bagaglio, S.
    Merli, M.
    Porrino, L.
    Pignataro, A. R.
    Boeri, E.
    Hasson, H.
    Lazzarin, A.
    Carbone, A.
    Morsica, G.
    Uberti-Foppa, C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S474 - S474
  • [44] Evaluation of the Role of the Immune Responses in Determining the Emergence of HCV Ns3 Resistance Mutations During Protease Inhibitor (PI) Therapy
    Abdel-hameed, Enass A.
    Rouster, Susan D.
    Ji, Hong
    Ulm, Ashley
    Hetta, Helal
    Sherman, Kenneth E.
    Shata, Mohamed Tarek M.
    GASTROENTEROLOGY, 2015, 148 (04) : S1095 - S1095
  • [45] CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS SEQUENTIALLY TREATED WITH BOCEPREVIR (SCH503034) AND/OR PEGYLATED INTERFERON ALFA-2B (PEG-IFN α-2B)
    Vermehren, Johannes
    Susser, Simone
    Karey, Ursula
    Forestier, Nicole
    Lange, Christian M.
    Hughes, Eric A.
    Ralston, Robert
    Tong, Xiao
    Zeuzem, Stefan
    Sarrazin, Christoph
    HEPATOLOGY, 2009, 50 (04) : 1040A - 1041A
  • [46] Diverse outcome of genotypic resistance analysis over time in two patients with transmitted reverse transcriptase inhibitor and protease inhibitor resistance mutations at primary infection
    Koelsch, KK
    Little, S
    Ignacio, CC
    Richman, DD
    Wong, JK
    ANTIVIRAL THERAPY, 2002, 7 : S71 - S71
  • [47] Mutations in the natural strains of NS3 protease domain that confer resistance to anti-HCV protease inhibitors in HIV/HCV coinfected patients
    Bagaglio, S.
    Uberti-Foppa, C.
    Alagna, L.
    Lodrini, C.
    Gallotta, G.
    Galli, L.
    Dispinseri, S.
    Lazzarin, A.
    Morsica, G.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S217 - S217
  • [48] Co-evolved protease substrate cleavage site mutations enhance protease inhibitor phenotypic resistance
    Kolli, M.
    Stawiski, E. W.
    Chappey, C.
    Parkin, N. T.
    Schiffer, C. A.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A49 - A49
  • [49] Signature substrate mutations associated with HIV-1 protease inhibitor resistance
    Kolli, M.
    Stawiski, E.
    Chappey, C.
    Parkin, N.
    Schiffer, C. A.
    ANTIVIRAL THERAPY, 2007, 12 : S144 - S144
  • [50] Signature substrate mutations associated with HIV-1 protease inhibitor resistance
    Kolli, M.
    Stawiski, E.
    Chappey, C.
    Parkin, N.
    Schiffer, C. A.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S144 - S144